欢迎访问《中国临床药理学与治疗学》杂志官方网站,今天是

中国临床药理学与治疗学 ›› 2001, Vol. 6 ›› Issue (1): 56-58.

• 论著 • 上一篇    下一篇

氯沙坦对充血性心衰患者心功能及循环NO/ET 的影响

王邦宁, 张传焕, 沈玉芳, 刘敏, 陈大年, 高丹屏   

  1. 安徽医科大学第一附属医院CCU, 合肥 230022
  • 收稿日期:2000-07-26 修回日期:2001-01-17 发布日期:2020-12-01
  • 作者简介:王邦宁, 女, 主任医师。

Effect of losartan on cardiac function and secretion of nitric oxide and endothelin in patients with congestive failure

WANG Bang-Ning, ZHANG Chuan-Huan, SHEN Yu-Fang, LIU Min, CHEN Da-Nian, GAO Dan-Ping   

  1. The First Affliated Hospital of Anhui Medical University, Hefei 230022
  • Received:2000-07-26 Revised:2001-01-17 Published:2020-12-01

摘要: 目的 探讨氯沙坦治疗充血性心衰(CHF) 的临床疗效及对循环NO 和内皮素(E T) 水平的影响。方法 60 例CHF 患者在常规治疗基础上随机加用氯沙坦(25 ~ 50 mg·d-1, 口服) 或依那普利(2.5 ~ 5 mg·d-1, 口服), 疗程12 w k 。观察治疗前后心功能、血浆NO 及ET 水平变化。30 例健康者作为正常对照组。结果 CHF 患者收缩和舒张功能参数异常, 血浆ET 及NO 水平较正常对照组显著升高(P<0.05 或P <0.01) 。治疗12 w k 后, 氯沙坦组心功能改善率为85 %, 依那普利组改善率为84 %, 心脏收缩和舒张功能参数均显著改善;血浆E T 及NO水平明显降低(P <0.01), NO/ET 比值显著升高(P <0.05), 两组间差异无统计学意义(P >0.05) 。结论 氯沙坦能明显改善CHF 患者心脏功能, 恢复NO 与E T 之间合成释放平衡, 这可能是氯沙坦治疗心衰的重要机制之一。

关键词: 氯沙坦, 充血性心力衰竭, 内皮素, 一氧化氮

Abstract: Aim To evalute the effects of losartan on the cardiac function and secretion of nitric oxide (NO) and endothelin (ET) in patients with congestive heart failure(CHF). Methods Sixty patients with class II ~ Ⅳ CHF were randomised to receive a 12 weeks of routine therapy either with losartan (n =30)to be added from 25 mg to 50 mg daily or with enalapril (n = 30) to be added from 2.5 mg to 5 mg daily. The cardiac systolic and diastolic funtion and the levels of NO and ET were observed before and after therapy respectively with 30 normal control subjects seving as control. Results The abnormal cardiac systolic and diastolic function parameter were present in patients with CHF. The ET and NO levels in CHF patients were significantly higher than those in the control group(P <0.05). NYHA function class was improved in 85% of losartan treated patients and in 84% of enalapril-treated patients after 12 weeks as compared with cardiac function at baseline. ET and NO levels were significantly reduced(P <0.01) NO/ ET ratio was increased (P <0.05) after 12 weeks of therapy in two active groups. Conclusion The systolic and diastolic functions of patients with CHF are greatly improved by losartan treatment, which reverses the imbalance of NO/ ET and it is suspected that this action may be another important mechanism of its treating heart failure

Key words: losartan, congestive heart failure, endothelin nitric oxide

中图分类号: